TRPV1

Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis

Retrieved on: 
Tuesday, March 29, 2022
Metabolism, Human, Osteoarthritis, Investment, Marketing, Diagnosis, Neck, III, Growth, Physical examination, Genetics, Common, Arthralgia, Pressure, Synovial membrane, Ageing, Research Triangle, Specialization, Tissue, Pain, Pain management, Joint, Arthropathy, RTX, Transience, MD, Quality of life, Safety, OA, TRPV1, Knee, Joint capsule, Animal, Patient, Ligament, Phase, Pharmaceutical industry, Dentistry, EU

AACHEN, Germany and RALEIGH, N.C., March 29, 2022 /PRNewswire/ --Grnenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grnenthal's asset resiniferatoxin (RTX).

Key Points: 
  • AACHEN, Germany and RALEIGH, N.C., March 29, 2022 /PRNewswire/ --Grnenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grnenthal's asset resiniferatoxin (RTX).
  • The Phase III trials will investigate the efficacy, safety and tolerability of RTX in patients with pain associated with osteoarthritis of the knee.
  • This agreement provides Grnenthal headroom for further investments in the execution of its growth strategy and the advancement of a promising pipeline into the clinic."
  • Under the terms of the agreement, NovaQuest will reimburse Grnenthal's investments into the clinical phase III programme of RTX and share the clinical development and approval risks with Grnenthal.

Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants

Retrieved on: 
Sunday, March 20, 2022
Serum, Private Securities Litigation Reform Act, Therapy, Risk, Vaccination, ACE2, Osteoarthritis, Trial of the century, WA1, Forward-looking statement, NAB, Furin, Vaccine, EUA, Volatile organic compound, Time-invariant system, Sciatica, Cancer, CEO, Severe acute respiratory syndrome coronavirus 2, PHN, U.S. Securities and Exchange Commission, Preprint, Pain, RTX, Autoimmune disease, Security (finance), Intention, RNA transfection, TRPV1, Mutation, Lists of countries and territories, GLOBE, Lance, Animal, Trigeminal neuralgia, RBD, SAN, Annual report, FDA, Patient, Infection, Antibody, Pharmaceutical industry, Generic drug, S1, Delta, Omicron, COVID-19

Sorrentos designer mRNA vaccine, utilizing a chimeric mRNA that incorporates the Delta receptor binding domain (RBD) into the Omicron spike protein, provided strong, broad-spectrum protection against both BA.1 and BA.2 sublineages of Omicron, and Delta variant in immunized animals.

Key Points: 
  • Sorrentos designer mRNA vaccine, utilizing a chimeric mRNA that incorporates the Delta receptor binding domain (RBD) into the Omicron spike protein, provided strong, broad-spectrum protection against both BA.1 and BA.2 sublineages of Omicron, and Delta variant in immunized animals.
  • Sorrento intends to develop and seek EUA approval of this next-generation mRNA vaccine in Mexico and other developing countries.
  • These changes result in enhanced transmissibility and breakthrough cases in the presence of antibodies induced by vaccination with the wild-type SARS-CoV-2 spike mRNA vaccines.
  • This novel designer chimeric mRNA vaccine may offer a powerful strategy to develop mRNA vaccines with universal protection against SARS-CoV-2 and its major VOCs.

Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure

Retrieved on: 
Wednesday, March 2, 2022
Risk, Private Securities Litigation Reform Act, TRPV1, Omicron, Volatile organic compound, COVID, Animal, Infection, Patient, Vaccine, Student, Forward-looking statement, Security (finance), Safety, Annual report, U.S. Securities and Exchange Commission, FDA, SAN, Therapy, RTX, Trigeminal neuralgia, Cancer, NAB, Travel, Long-term care, School, Pain, Trial of the century, Sciatica, Autoimmune disease, Clinical trial, IND, Osteoarthritis, Severe acute respiratory syndrome coronavirus 2, PHN, Antibody, Atmosphere, GLOBE, Pharmaceutical industry, Generic drug, COVID-19

STI-9199 neutralizing antibody (nAb) nasal drops prevent productive infections when given to animals 24 hours before they are exposed to COVID.

Key Points: 
  • STI-9199 neutralizing antibody (nAb) nasal drops prevent productive infections when given to animals 24 hours before they are exposed to COVID.
  • SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that new preclinical results demonstrate that pretreating an animal with intranasal neutralizing antibody (STI-9199) twenty-four (24) hours prior to being exposed to SARS-CoV-2 virus prevents productive infection in the treated animals.
  • These data suggest that an individual who is at high risk of exposure to the SARS-CoV-2 virus could potentially be protected by taking STI-9199 nasal neutralizing antibody.
  • For example, if a member of a household becomes infected, the others in the house could be treated with intranasal STI-9199 to potentially prevent them from being infected.

Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses

Retrieved on: 
Wednesday, March 2, 2022
Risk, Private Securities Litigation Reform Act, TRPV1, Omicron, Patient, Pharmacokinetics, Vaccine, Forward-looking statement, Security (finance), Safety, Annual report, U.S. Securities and Exchange Commission, FDA, SAN, Therapy, RTX, Trigeminal neuralgia, Cancer, Pain, EUA, Trial of the century, Sciatica, Emergency Use Authorization, Autoimmune disease, IND, Osteoarthritis, Severe acute respiratory syndrome coronavirus 2, PHN, Antibody, GLOBE, Pharmaceutical industry, Generic drug, COVID-19

FDA granted IND clearance today for STI-9199 (COVISHIELD) for a Phase 1 safety and pharmacokinetic study in healthy volunteers.

Key Points: 
  • FDA granted IND clearance today for STI-9199 (COVISHIELD) for a Phase 1 safety and pharmacokinetic study in healthy volunteers.
  • Initial trials are expected to be followed by a multinational Phase 2/3 trial in both mild and moderate COVID-19 patients.
  • STI-9199 has demonstrated in vitro and in vivo activity against all SARS-CoV-2 variants tested, including the Omicron strain BA.1, Omicron BA.1+R346K and Omicron BA.2.
  • The Phase 1 study will be at a single clinical site in San Diego and will be followed by multinational (USA, UK and Mexico) Phase 2/3 trials.

American Society for Laser Medicine and Surgery Hosts its 41st Annual Conference

Retrieved on: 
Wednesday, February 23, 2022
Nobel Prize, Nobel Prize in Physiology or Medicine, Medical imaging, San Diego Convention Center, National Institute of Biomedical Imaging and Bioengineering, CME, Pain, Metabolism, Mark (given name), NIH, Education, COVID-19, Vascular disease, Cutting edge, National, Biological engineering, Breast cancer, Wand, Temperature, Respiration, Industry, TRPV1, FRCP, Blood pressure, Ion, DRS, Convention, Laser, National Primate Research Exhibition Hall, Conference, EBD, 2021 Essex County Council election, Annual conferences, Knowledge, PIEZO2, Society, Research, Program, National Institute, Doctor of Philosophy, Health, Pharmaceutical industry, Medical device, Medicine, Physiology, MD

WAUSAU, Wis., Feb. 23, 2022 /PRNewswire-PRWeb/ --For over 40 years, the Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS) has been the premier meeting for scientific studies and clinical breakthroughs in laser and energy-based technologies for patient care.

Key Points: 
  • WAUSAU, Wis., Feb. 23, 2022 /PRNewswire-PRWeb/ --For over 40 years, the Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS) has been the premier meeting for scientific studies and clinical breakthroughs in laser and energy-based technologies for patient care.
  • ASLMS 2022, the 41st Annual Conference, will bring the world's leading clinicians and scientists together to explore the most recent advancements.
  • "I am very much looking forward to our Annual Conference in 2022, which will be the first in-person meeting since 2019," said Henry H.L.
  • Andrea Alstad, American Society for Laser Medicine and Surgery, 7158459283, [email protected]

Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses

Retrieved on: 
Tuesday, February 22, 2022
Risk, Security (finance), Therapy, Osteoarthritis, RTX, Protein, IND, Private Securities Litigation Reform Act, Infection, VOC, Drug discovery, PHN, Viral load, NP, Safety, U.S. Securities and Exchange Commission, Lance, Review, Sciatica, SAN, Real-time, Vaccination, Pain, NAB, Antibody, Trial of the century, Vaccine, Alpha, Volatile organic compound, EUA, Forward-looking statement, Trigeminal neuralgia, Patient, SARS, GLOBE, GMP, Omicron, Method, IV, Annual report, Technology transfer, Clinical trial, TRPV1, VSV, FDA, Autoimmune disease, Cancer, Pharmaceutical industry, Generic drug, COVID-19, Severe acute respiratory syndrome coronavirus 2, Delta, Lambda

STI-9167 neutralizing antibody (nAb) maintains high neutralization potency against the recently emerging Omicron sublineage BA.2 as was previously demonstrated for the Omicron sublineage BA.1 viruses, including Omicron BA.1 (+R346K mutation).

Key Points: 
  • STI-9167 neutralizing antibody (nAb) maintains high neutralization potency against the recently emerging Omicron sublineage BA.2 as was previously demonstrated for the Omicron sublineage BA.1 viruses, including Omicron BA.1 (+R346K mutation).
  • The BA.2 Omicron virus is reported to have 50% more enhanced transmissibility as compared to the BA.1 Omicron viruses and may cause potentially similar disease severity as the Delta virus.
  • Using VSV pseudotyped viruses, STI-9167 neutralization potency was benchmarked against antibody reagents based on EUA-approved SARS-CoV-2 nAbs.
  • COVISHIELD (STI-9167) is an intravenous (IV) formulation and COVISHIELD IN (STI-9199) is a proprietary IN formulation of COVISHIELD.

Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™

Retrieved on: 
Thursday, February 17, 2022
Patient, Platinum, Autoimmune disease, Cancer, CEO, Trigeminal neuralgia, COVID, Risk, Acquisition, OEM, TRPV1, Lod, Forward-looking statement, U.S. Securities and Exchange Commission, Organic compound, Vaccine, SAN, RTX, Private Securities Litigation Reform Act, Security (finance), Ownership, Annual report, GLOBE, Omicron, Gold, Pain, Volatile organic compound, Therapy, FDA, Sale, Diagnosis, Â, Fecal occult blood, Limiting factor, Antibody, PHN, Sciatica, Severe acute respiratory syndrome coronavirus 2, Osteoarthritis, CE, Trial of the century, Industry, Pregnancy, Medical device, Pharmaceutical industry, Generic drug, COVID-19

In response to increasing product demand, Sorrento has invested and becomes a majority owner with an option to acquire 100% of FortuneBio, a diagnostic product manufacturer with dozens of approved diagnostic products on the market, and is currently Sorrentos exclusive OEM manufacturer for COVISTIX.

Key Points: 
  • In response to increasing product demand, Sorrento has invested and becomes a majority owner with an option to acquire 100% of FortuneBio, a diagnostic product manufacturer with dozens of approved diagnostic products on the market, and is currently Sorrentos exclusive OEM manufacturer for COVISTIX.
  • SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the acquisition of a majority ownership of Zhengzhou Fortune Bioscience Co., Ltd. (FortuneBio).
  • This acquisition is in response to dramatically increasing demands worldwide and planned product build-up in anticipation of potential additional approvals for Sorrentos COVISTIXTM COVID-19 VIRUS Rapid Antigen Detection Test.
  • COVISTIX demand is increasing rapidly worldwide due to its high sensitivity as compared with other EUA-approved tests.

Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor

Retrieved on: 
Wednesday, February 2, 2022
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, News, Safety, Patient, Rehabilitation, TKA, Sports medicine, Food, University, University of Rochester Medical Center, Scripps Research, Korea Disease Control and Prevention Agency, UCSF, Nobel Prize, TRPV1, Elective surgery, Death, Anesthetic, Doctor of Public Health, ERG, Center, Research, URMC, U.S. News & World Report, Medicine, Hospital, Ambulatory Surgery Center Association, Temperature, Capsaicin, Science, Prodrug, Target, Fast track (FDA), Pain, Outpatient surgery, Regulation of tobacco by the U.S. Food and Drug Administration, Nobel Prize in Physiology or Medicine, Therapy, Discovery (observation), Concentric objects, OTC, Mark (given name), Traffic, Pharmaceutical industry, Analgesic, Physiology

Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced two important Phase 3 clinical relationships for its lead product candidate, vocacapsaicin.

Key Points: 
  • Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced two important Phase 3 clinical relationships for its lead product candidate, vocacapsaicin.
  • URMC will participate in the vocacapsaicin Phase 3 clinical trials and develop innovative methods to capture vocacapsaicins benefit to patient recovery and rehabilitation.
  • Concentric Analgesics lead product candidate for postsurgical pain is a proprietary first-in-class prodrug therapeutic that rapidly converts to capsaicin, a potent TRPV1 agonist.
  • Concentric Analgesics is a clinical-stage, biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics.

Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Retrieved on: 
Friday, January 28, 2022
RTX, Infection, CEO, Safety, Private Securities Litigation Reform Act, Forward-looking statement, Risk, Patient, Therapy, Cell, SAN, EC50, Trial of the century, Mpro, Liver, Ritonavir, Omicron, Human, TRPV1, S, Sciatica, Cancer, Osteoarthritis, U.S. Securities and Exchange Commission, Autoimmune disease, PHN, Annual report, Vaccine, GLOBE, Pain, Volatile organic compound, Time, Severe acute respiratory syndrome coronavirus 2, EUA, FDA, Security (finance), Antibody, Trigeminal neuralgia, Pharmaceutical industry, Generic drug, Delta, COVID-19

STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans.

Key Points: 
  • STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans.
  • SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays.
  • The world is experiencing a huge wave of infection with the Omicron variant of SARS-CoV-2, and current vaccines and EUA-approved antibodies offer diminished protection against Omicron transmission and infection.
  • Notably, in an Omicron S protein-mediated pseudovirus entry assay, STI-1558 effectively inhibited pseudovirus entry into cells, whereas EUA-approved nirmatrelvir showed no inhibition.

Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling Phase 3 Studies for Vocacapsaicin

Retrieved on: 
Wednesday, January 26, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Clinical Trials, DMD, Regulation of tobacco by the U.S. Food and Drug Administration, GSK China scandal, Executive, Business studies, List of professional associations in the United Kingdom, Institute of Certified Management Accountants, University of West London, Gilead Sciences, Standard of care, Korea Disease Control and Prevention Agency, Harvard Business School, GSK, LLC, Patient, Investment, Mergers and acquisitions, News, Capsaicin, Food, Head, University, TRPV1, OTC, Therapy, Death, Concentric objects, Analgesic, Association, U.S. News & World Report, CCMP Capital, Program, Time, Fast track (FDA), Chartered Institute of Management Accountants, Georgetown University, Prudential Securities, Center, Board, NDA, CCMP, Traffic, MBA, Anesthetic, GlaxoSmithKline, Pharmaceutical industry, Management

In addition, the company announced the appointments of Paul R. Carter and Jonathan R. Lynch to its board of directors.

Key Points: 
  • In addition, the company announced the appointments of Paul R. Carter and Jonathan R. Lynch to its board of directors.
  • Concentric intends to use the proceeds from the financing to further fund Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for postsurgical pain.
  • Mr. Carter is currently a Board Director for four publicly listed biopharma companies, which include HutchMed PLC, Mallinckrodt Pharmaceuticals plc, Immatics NV, and VectivBio Inc.
  • He also is a member of the board of directors of several private companies, including Evox Therapeutics Ltd.